Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | KDM1A | O60341 | 5/20 | 0.41 |
| ▸ | SAT1 | P21673 | 3/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23868460 | 1.00 | CYP2C19 (0.50) | CYP2C19MEN1GLAKMT2ATSHR | |
| SCHEMBL22548516 | 0.93 | CYP2C19 (0.52) | CYP2C19MEN1GLAKMT2ATSHR | |
| SCHEMBL7107023 | 0.93 | CYP2C19 (0.52) | CYP2C19MEN1GLAKMT2ATSHR | |
| SCHEMBL24759345 | 0.91 | CYP2C19 (0.50) | CYP2C19MEN1GLAKMT2ATSHR | |
| SCHEMBL23842136 | 0.91 | CYP2C19 (0.50) | CYP2C19MEN1GLAKMT2ATSHR | |
| SCHEMBL5932551 | 0.90 | TSHR (0.41) | CYP2C19MEN1GLAKMT2ATSHR | |
| SCHEMBL23221203 | 0.86 | CYP2C19 (0.40) | CYP2C19MEN1GLAKMT2ATSHR | |
| SCHEMBL7107370 | 0.84 | — | — | |
| SCHEMBL20906860 | 0.83 | TSHR (0.48) | CYP2C19MEN1GLAKMT2ATSHR | |
| SCHEMBL22511778 | 0.83 | TSHR (0.42) | CYP2C19MEN1GLAKMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11718631-B2 | Sulphonamides and compositions thereof for treating conditions associated with NLRP activity | NOVARTIS AG (CH) | 2023-08-08 | — | — | US | disclosed |
| EP-3542824-A1 | Ras PROTEIN DEGRADATION INDUCING MOLECULE AND PHARMACEUTICAL COMPOSITION | Tokyo University of Science Foundation (JP) | 2019-09-25 | — | — | EP | disclosed |
| EP-2094698-A1 | SUBSTITUTED 6-PHENYL-PYRIDO [2,3-D]PYRIMIDIN-7-ONE DERIVATIVES AS KINASE INHIBITORS AND METHODS FOR USING THE SAME | F. Hoffmann-Roche AG (CH) | 2009-09-02 | — | — | EP | disclosed |
| WO-2008055842-A1 | SUBSTITUTED 6-PHENYL-PYRIDO [2,3-D] PYRIMIDIN-7-ONE DERIVATIVES AS KINASE INHIBITORS AND METHODS FOR USING THE SAME | F. HOFFMANN-LA ROCHE AG (CH) | 2008-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11718631-B2 | Sulphonamides and compositions thereof for treating conditions associated with NLRP activity | NLRP1, NLRP3, NOD1 | CYP2C19 2080/4885MEN1 3988/4885GLA 2897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.